GnRH-α联合米非司酮对子宫腺肌病患者卵巢功能及子宫体积的影响  

Effect of GnRH-αcombined with mifepristone on ovarian function and uterine volume in patients with adenomyosis

作　　者：朱宏 郭祥瑞 马玲 Zhu Hong;Guo Xiangrui;Ma Ling(Gynecology Department,The First Affiliated Hospital of Bengbu Medical College,Bengbu Anhui 233000,China;Gynecology Department,Anhui No.2 Provincial People's Hospital,Hefei 230041,China)

机构地区：[1]蚌埠医学院第一附属医院妇科,安徽蚌埠233000 [2]安徽省第二人民医院妇科,合肥230041

出　　处：《保健医学研究与实践》2022年第11期62-66,共5页Health Medicine Research and Practice

基　　金：安徽省高校自然科学研究重点项目(KJ2021A1262)。

摘　　要：目的探讨促性腺激素释放激素激动剂(GnRH-α)联合米非司酮对子宫腺肌病患者卵巢功能及子宫体积的影响。方法选取2020年1月—2021年12月于蚌埠医学院第一附属医院就诊的100例子宫腺肌病患者,采用随机数字表法分为对照组与研究组,每组50例。对照组患者采用米非司酮治疗,研究组患者采用GnRH-α联合米非司酮治疗,比较2组患者治疗前后卵巢功能、子宫体积、子宫内膜厚度、月经量、痛经程度评分、心理及疼痛评分变化,同时比较2组患者治疗效果及不良反应发生情况。结果2组患者治疗后血清卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E_(2))水平均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。2组患者治疗后子宫体积及子宫内膜厚度均小于治疗前,且研究组小于对照组,差异均有统计学意义(P<0.05)。2组患者治疗后月经失血图评分法(PBAC)及疼痛视觉模拟评分法(VAS)评分均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。2组患者治疗后汉密尔顿焦虑量表(HAMA)及汉密尔顿抑郁量表(HAMD)评分均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。研究组患者治疗总有效率为96.00%(48/50),高于对照组的78.00%(39/50),差异有统计学意义(χ^(2)=7.162,P=0.007)。研究组患者不良反应发生率为8.00%(4/50),低于对照组的26.00%(13/50),差异有统计学意义(χ^(2)=5.741,P=0.017)。结论GnRH-α联合米非司酮可改善子宫腺肌病患者卵巢功能,缩小子宫体积及子宫内膜厚度,减少月经量,缓解疼痛,改善性激素分泌,安全性较好。Objective To investigate the effect of gonadotropin-releasing hormone agonist(GnRH-α)combined with mifepristone on ovarian function and uterine volume in patients with adenomyosis.Methods A total of 100 patients with adenomyosis who visited the First Affiliated Hospital of Bengbu Medical College from January 2020 to December 2021 were randomly allocated to a control group and an experimental group,with 50 cases in each group.The patients in the control group received mifepristone,and the patients in the experimental group GnRH-αcombined with mifepristone.The changes in ovarian function,uterine volume,endometrial thickness,menstrual volume,dysmenorrhea score,and psychological and pain scores before and after treatment were compared between the two groups.The therapeutic efficacy and adverse reactions were also compared between the two groups.Results The serum levels of follicle-stimulating hormone(FSH),luteinizing hormone(LH),and estradiol(E_(2))in the two groups after treatment were significantly lower than those before treatment,with the experimental group lower than the control group(P<0.05).Uterine volume and endometrial thickness after treatment in the 2 groups were significantly smaller than those before treatment,with the experimental group smaller than the control group(P<0.05).The Pictorial Blood Loss Assessment Chart(PBAC)and visual analogue scale(VAS)scores after treatment in the two groups were significantly lower than those before treatment,with the experimental group lower than the control group(P<0.05).Hamilton Anxiety Rating Scale(HAMA)and Hamilton Depression Rating Scale(HAMD)scores of patients in the 2 groups after treatment were significantly lower than those before treatment,with the experimental group lower than the control group(P<0.05).The overall response rate in the experimental group was 96.00%(48/50),which was higher than that in the control group(78.00%,39/50),with statistical significance(χ^(2)=7.162,P=0.007).The incidence rate of adverse reactions in the experimental group was 8.00

关 键 词：促性腺激素释放激素激动剂 米非司酮 子宫腺肌病 卵巢功能 子宫体积 

分 类 号：R711.74[医药卫生—妇产科学]